Allogene Therapeutics shareholders elect four Class II directors, approve say-on-pay and auditor ratification

Proposal 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement for the Annual Meeting. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 73,082,912 31,751,974 1,939,920 13,946,626

Proposal 3. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 120,675,447 36,870 9,115 0

Proposal 1. Election of Directors The Company’s stockholders elected the four persons listed below as Class II Directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Deborah Messemer 90,975,252 15,799,554 13,946,626 Vicki Sato, Ph.D. 105,736,345 1,038,461 13,946,626 Todd Sisitsky 86,678,264 20,096,542 13,946,626 Owen Witte, M.D. 88,677,813 18,096,993 13,946,626